
    
      Participants who meet study eligibility will receive or continue to receive blinatumomab by
      continuous IV infusion for 28 days and also receive pembrolizumab (by IV infusion over 30
      minutes) on day 12 of cycle 1 and day 5 of cycle 2.

      One cycle lasts 35 days and patients will receive 2 cycles of therapy.
    
  